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Abstract
 
Altered peptide ligands (APLs) and their antagonistic or partial agonistic character–influencing T
cell activation have mainly been studied in vitro Some studies have shown APLs as a viral escape
 
mechanism from cytotoxic CD8
 
  
 
T cell responses in vivo. However, whether infection or super-
infection with a virus displaying an antagonistic T cell epitope can alter virus–host relationships via
inhibiting T cell–mediated immunopathology is unclear. Here, we evaluated a recently described
CD4
 
  
 
T cell escape lymphocytic choriomeningitis virus (LCMV) variant that in vitro displayed
antagonistic characteristics for the major histocompatibility complex class II–restricted mutated
epitope. Mice transgenic for the immunodominant LCMV-specific T helper epitope that usually
succumb to wild-type LCMV-induced immunopathology, survived if they were simultaneously
coinfected with antagonistic variant but not with control virus. The results illustrate that a coin-
fecting APL-expressing virus can shift an immunopathological virus–host relationships in favor of
host survival. This may play a role in poorly cytopathic long-lasting virus carrier states in humans.
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Introduction
 
Altered peptide ligands (APLs)
 
*
 
 were originally described as
modified MHC class II peptides with a single amino acid
change, which in vitro induced cytokine secretion without
 
proliferation of the CD4
 
  
 
T cells. This contrasted with activa-
tion and proliferation after stimulation with the WT peptide
(1, 2). Subsequently, complete antagonistic (3, 4) or partial ag-
onistic features (5, 6) of APLs have been described. Most of
these data were collected with CD4
 
  
 
T cells in vitro (1) or by
peptide immunization in vivo (7–9). The general hope is that
such APL might be used to interfere with, or prevent the in-
duction of, autoimmunity. Two clinical therapeutic trials have
used CD4
 
  
 
T helper cell–specific APL peptides in multiple
sclerosis patients (10, 11) without finding any clear effect on
disease progression. Mutations of CD8
 
  
 
cytotoxic (CTL)
epitopes with APL features have been described as a possible
viral escape mechanism from protective cytotoxic T cell re-
sponses. During HIV (12, 13), hepatitis B (14), hepatitis C
(15), and lymphocytic choriomeningitis virus (LCMV; 16–18)
infections mutated MHC class I epitopes have been identified
in the viral genome of infected patients or mice. The possibil-
ity that the presence of both WT and APL virus in vivo can
influence CD4
 
  
 
or CD8
 
  
 
T cell immune responses and the
outcome of disease caused by non or poorly cytopathic vi-
ruses, however, has not been studied so far.
 
We have recently analyzed a CD4
 
  
 
T cell escape mutant of
the RNA virus LCMV-WE, a noncytopathic mouse patho-
gen (19). This escape mutant arose in LCMV-WE–infected
mice treated with TCR transgenic (tg) CD4
 
  
 
T cells specific
for the major MHC class II LCMV glycoprotein peptide gp61
(19). The deleted single point mutation in the viral RNA
leads to an amino acid substitution at position 75 of the
LCMV glycoprotein I from K to R. When analyzed in vitro,
the peptide gp61-75R was able to antagonize proliferation
and cytokine production of the WT peptide, thereby reveal-
ing activities as shown for APLs. Because the assessment of T
cell–mediated immunoprotection is usually sensitive to low T
cell numbers over a narrow range, whereas susceptibility to
immunopathological disease is dependent upon large numbers
of effector T cells over a rather broad range, the latter situation
should offer the possibility to evaluate the effects of APL in
LCMV-induced CD4
 
  
 
T cell–dependent immunopathology.
 
Materials and Methods
 
Mice.
 
Smarta1/2, TNFR1
 
 
 
/
 
 
 
, and Fas
 
 
 
/
 
  
 
mice were pur-
chased from the Institute für Labortierkunde (University of Zur-
ich, Zurich, Switzerland) and kept under specific pathogen-free
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conditions. TNFR1
 
 
 
/
 
  
 
knockout mice were backcrossed to
Smarta2 tg mice. Genotype was confirmed by PCR (TNFR1
knockout) and FACS
 
® 
 
(Smarta TCR).
 
Virus.
 
LCMV strain WE, Docile (provided by F. Lehmann-
Grube, Heinrich Pette Institute, Hamburg, Germany), and Arm-
strong (provided by R. Ahmed, Emory University School of
Medicine, Atlanta, GA) were propagated on L929 cells. Mice
were infected intravenously with the indicated dose.
 
Peptides.
 
The following peptides were used: gp61 (aa61-80):
GLNGPDIYKGVYQFKSVEFD; gp61-75R (aa61-80): GLNG-
PDIYKGVYQF
 
R
 
SVEFD; and p8 (aa415-433): SSKHQVFEH-
PHIQDAASQL.
 
FACS
 
®
 
.
 
Peripheral blood was collected by retroorbital bleed-
ing and the lymphocytes were stained with rat anti–mouse CD4
tri-color conjugated antibody (Caltag), anti–mouse CD69 FITC-
conjugated antibody (BD Biosciences), and anti–mouse CD62L-
PE–conjugated antibody (BD Biosciences), and then analyzed with
the Becton Dickinson FACScan™. The determination of virus ti-
ter by plaque assay was performed as previously described (20).
 
Immunohistochemistry.
 
This was performed on cryosection and
as previously described (21).
 
CD8 Depletion.
 
CD8 depletion was performed with mono-
clonal rat antibodies as previously described (19).
 
Statistical Analysis.
 
Statistical analysis was performed with the
one-tailed Mann-Whitney U test using GraphPad Prism3.00 for
Windows (GraphPad Software). P 
 
  
 
0.05 was interpreted as sta-
tistically significant.
 
Results and Discussion
 
As an in vivo readout of the APL activities of the mutated
virus we used CD4
 
  
 
TCR tg mice (Smarta1 mice in which
the CD41 T cells are specific for the MHC class II LCMV
glycoprotein peptide gp61; 22), which express the tg TCR
in 
 
 
 
98% of the CD4
 
  
 
T cells and have only low numbers of
CD8
 
  
 
T cells. Although this tg CD4
 
  
 
T cell condition dis-
playing a limited T cell repertoire represents a model situa-
tion, it reduces complexities and may allow for the determi-
nation of the key parameter change. Smarta mice were
infected with different LCMV strains. In order of increasing
replication kinetics and hepatotropism, they are: Arm-
strong  (LCMV-Armstrong), WE WT (LCMV-WE
 
WT
 
),
Docile (LCMV-Docile), or the mutated LCMV-WE APL
virus (LCMV-WE
 
APL
 
). Mice infected with different LCMV
strains show strain-dependent clinical courses and clearance
characteristics (23). Although LCMV-Docile and LCMV-
Armstrong differ at several other sites, they differ only at
position 63 from the gp61-80 helper epitope of LCMV-
WE
 
WT
 
. However, this change is irrelevant for the recogni-
tion and activation of the tg Smarta CD4
 
  
 
T cells in vitro
(unpublished data) and in vivo. Upon infection with 200
plaque-forming units (pfu) LCMV-WE
 
WT
 
, Smarta1 animals
showed rapid signs of systemic disease, lost 22% of their
body weight, and died within 11 to 14 d (Fig. 1 a). Similarly,
infection with 200 pfu LCMV-Docile was lethal within 8 to
10 d and the mice showed an accelerated reduction in body-
weight when compared with LCMV-WE
 
WT
 
 (Fig. 1 a).
Mice infected with a higher dose (2 
 
  
 
10
 
4 
 
pfu) of the less
rapidly replicating LCMV-Armstrong lost up to 35% of
bodyweight within 12 to 15 d. The mortality was 80% (Fig.
 
1 a). In contrast, after infection with the CD4
 
  
 
T cell escape
virus (LCMV-WE
 
APL
 
) all animals survived independently of
the applied dose (Fig. 1 a). After infection with 200 pfu
LCMV-WE
 
APL
 
, the bodyweight reduction was delayed by 8
to 10 d compared to LCMV-WE
 
WT
 
 and maximal weight
loss was around 20% on day 20. The mice completely recov-
ered thereafter (Fig. 1 a). Similarly, after infection with 2 
 
 
 
10
 
4 
 
pfu LCMV-WE
 
APL
 
, the bodyweight reduction was de-
layed by 2 to 4 d compared to LCMV-WE
 
WT
 
, LCMV-
Docile, or LCMV-Armstrong infection. Again, the maximal
bodyweight reduction was 
 
 
 
20% and all mice survived (Fig.
1 a). The amount of replicating virus in the blood correlated
well with the infecting virus dose except for LCMV-Docile,
which is known to replicate faster in vivo than the others.
All surviving mice became chronic LCMV carriers (Fig. 1
b). The tg CD4
 
  
 
T cells were activated upon infection with
all LCMV strains, as shown by the up-regulation of the early
T cell activation marker CD69 (Fig. 1 c) and the down-reg-
ulation of the late T cell activation marker CD62L (Fig. 1 d).
The intensity of CD69 up-regulation at day 4 correlated
well with the reduction in bodyweight. Surprisingly and in
contrast to the stimulation results obtained in vitro, APL vi-
rus–infected mice also showed CD69 up-regulation and
CD62L down-regulation, although less extensively than that
observed in LCMV-Docile– or LCMV-WE
 
WT
 
–infected
mice (Fig. 1, c and d). Interestingly, upon infection of tg
mice with lactate dehydrogenase elevating virus (LDV), we
also observed a slight CD69 up-regulation (Fig. 1 c) and a
comparable CD62L down-regulation (Fig. 1 d) after infec-
tion with LCMV-WE
 
APL
 
. This suggests a general rather than
a specific effect, indicating that the observed CD4
 
  
 
T cell ac-
tivation after LCMV-WE
 
APL
 
 and LDV could partially be
due to CD4
 
  
 
T cell bystander activation in a tg, almost
monoclonal, situation (24). In addition, viral revertants or
minimal contamination of quasispecies in the viral stocks
could be responsible for the observed CD4
 
  
 
T cell activation
after LCMV-WE
 
APL
 
 infection. We also performed intracel-
lular IFN
 
  
 
staining 8 d after infection with 200 pfu LCMV-
WE
 
WT
 
 or LCMV-WE
 
APL
 
. However, we were not able to
observe any relevant IFN
 
  
 
production in the spleen com-
pared to the situation in nontransgenic C57BL/6 mice (un-
published data). This correlates with the down-regulated
TCR, which is usually paralleled by CD69 up-regulation,
and a dilution by nonprimed TCR tg CD4
 
  
 
T cells in this
almost monoclonal situation. However, activation and pro-
liferation of the Smarta TCR tg CD4
 
  
 
T cells after adoptive
transfer experiments has been described in several prior pub-
lications (19, 22, 25–27).
To further analyze the mechanism of LCMV-induced
cachexia and mortality in Smarta mice, we backcrossed
Smarta2 mice with TNFR1
 
 
 
/
 
  
 
mice. Due to logistical rea-
sons, Smarta2 mice, which have near normal CD8
 
  
 
T cell
levels, were used. After CD8 depletion by monoclonal
anti-CD8 antibodies, Smarta2 mice behave identically to
Smarta1 mice, not only in regard to mortality but also in
regard to protection by the LCMV-WE
 
APL
 
 (unpublished
data). In the absence of CD8
 
  
 
T cells, Smarta 
 
  
 
TNFR1
 
 
 
/
 
 
 
double tg mice were protected from death when infected 
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with LCMV-WE
 
WT
 
 at a dose of 200 pfu (Fig. 1 e). Similar
results were obtained with 2 
 
  
 
10
 
6 
 
LCMV-Docile (unpub-
lished data). In contrast, the backcrossing of Smarta2 mice
with Fas knockout mice could not prevent death when
mice were infected with LCMV-Docile (unpublished
data). This indicates that LCMV-induced disease in Smarta
mice is mainly mediated by CD4
 
  
 
T cells mediated via the
action of TNF
 
 
 
. This is similar to the situation in perforin
knockout mice, in which LCMV-induced cachexia, ane-
mia, and mortality is also mediated by TNF
 
  
 
(28).
To evaluate the antagonistic capacities of the escape
gp61 peptide, Smarta1 mice were immunized with 200 
 
 
 
g
of the gp61-75R or the gp61 WT peptide in IFA s.c. Di-
rect immunization with peptides was more efficient than
immunization with peptide-loaded dendritic cells (unpub-
lished data). No CD4
 
  
 
T cell activation was observed upon
immunization with 200 
 
 
 
g gp61-75R in IFA, but Smarta1
mice treated with the WT peptide died of generalized im-
munopathology within 1 to 2 d (unpublished data). Treat-
ment on day 0 and 4 with 200 
 
 
 
g gp61-75R in IFA s.c.
delayed lethal immunopathology by 3 to 4 d in Smarta1
 
mice infected intravenously with 20 pfu LCMV-WE
 
WT
 
(Fig. 2 a). The initial bodyweight loss was reduced and
fewer CD4
 
  
 
T cell were activated in comparison with 20
pfu LCMV-WE
 
WT
 
 alone or in combination with the irrel-
evant H2-IA
 
b
 
–presented vesicular stomatitis virus helper
epitope p8 (Fig. 2, a–c). This was paralleled by a reduction
in CD4
 
  
 
T cell activation depicted by a reduced CD69 up-
regulation (Fig. 2 c). Interestingly, survival was not pro-
longed when mice were treated with the antagonistic
gp61-75R peptide every second day (unpublished data).
Upon infection with a higher dose of LCMV-WE
 
WT
 
 (200
pfu; Fig. 2, d and e) bodyweight loss and CD4
 
  
 
T cell acti-
vation (CD69 up-regulation) were slightly, but not statisti-
cally significantly reduced when LCMV was injected with
200 
 
 
 
g of the antagonistic gp61-75R and death was de-
layed by 1 d (Fig. 2 d). These results showed a dose-depen-
dent action of the mutated peptide in vivo during a virus
infection and indicated that the initial presence of the an-
tagonistic peptide was crucial for prolonged survival.
In vitro, APL effects are usually observed with specific
CD4
 
  
 
T cells at 10–100-fold excess of the APL peptide
Figure 1. Virus-induced immunopathology. (a)
Smarta1 mice were infected intravenously with 200 pfu
LCMV-WEWT (  ), LCMV-Docile ( ), or LCMV-
APL ( ), or with 2   104 pfu LCMV-Armstrong ( ),
LCMV-WEAPL ( ), or LDV ( ). Bodyweight (n   3
or 4 mice per group) and mortality rate (cross repre-
sents all mice used) are indicated. (b) Virus titers were
measured in the blood (n   3 or 4 per group). The ac-
tivation of blood CD4  T cells was measured by (c)
CD69 up-regulation (n   3 or 4 per group) and (d)
CD62L down-regulation (n   3 or 4 per group). (e)
Smarta2 mice backcrossed to TNFR1 /  ( , n   5),
TNFR1 /  ( , n   5), or Smarta2 ( , n   3) were
CD8 depleted on days 3 and 1 and infected with 200
pfu LCMV-WEWT on day 0, respectively. The mortal-
ity rate was measured.1042 Protection from Immunopathology by Altered Peptide Ligand Virus In Vivo
against a submaximal WT peptide concentration. To exam-
ine APL effects in vivo during an infection we used the
gp61-75R peptide that displayed the antagonistic activity in
vitro at a 100-fold excess against the WT gp61 peptide (19).
The dose of WT peptide cannot be determined during a vi-
rus infection, but it is probably high. With the LCMV-
WEAPL we could now test the effects of APL not only with
peptide treatment but also by using the APL virus. The ef-
fects of LCMV-WEAPL were assessed in vivo by coinfecting
Smarta1 mice with different doses of LCMV-WEAPL and
LCMV WT strains LCMV-WEWT or LCMV-Docile at a
ratio of 1:1 to 1:100, respectively. The infection of Smarta1
mice with 200 pfu LCMV-Docile and 200 pfu LCMV-
WEAPL could not prevent lethal immunopathology (Fig. 3
a). The body weight reduction was comparable (Fig. 3 b),
whereas CD4  T cell activation was significantly reduced
7 d after infection in regard to CD62L down-regulation,
but no statistical difference in CD69 up-regulation could be
observed (Fig. 3, c and d). Mice exhibited signs of systemic
disease upon infection with 200 pfu LCMV-WEWT plus
200 pfu LCMV-WEAPL, but the mortality rate was reduced
to 20% (Fig. 3, a–d). The infection of mice with 200 pfu
LCMV-Docile plus 2   104 pfu LCMV-WEAPL resulted in
a wasting disease but the mice recovered after 30 d (Fig. 3, a
and b). Compared to infection with LCMV-Docile alone,
the coinfection resulted in a statistically significant delay of
the tg CD4  T cell activation with regard to CD69 up-reg-
ulation and CD62L down-regulation (Fig. 3, c and d). After
infection with 200 pfu LCMV-WEWT plus a 100-fold ex-
cess of LCMV-WEAPL (2   104 pfu), the bodyweight loss
was considerably less severe and mice were clinically in
much better condition (Fig. 3, a and b). In addition, the tg
CD4  T cells were statistically significantly less activated
with regard to CD69 up-regulation at days 4 and 12 (Fig. 3,
c and d). All mice became chronic LCMV carriers, although
the initial virus load in the blood at 4 d after infection was
reduced in LCMV-WEAPL–infected mice coinfected with
LCMV-Docile compared to mice infected with LCMV-
Docile alone, although not statistically significant (Fig. 3 e).
To examine whether protection by the variant virus was
due to a different virus tropism in the relevant organs, we
evaluated the distribution of LCMV-WEWT and LCMV-
WEAPL in vivo. We used C57BL/6 WT mice because in the
absence of CD8  T cells, as is the case in Smarta1 mice, viral
distribution is very rapid so that minor differences can not
be detected. We could not observe any difference with re-
gard to tropism after 200 pfu infection with LCMV-WEWT
or LCMV-WEAPL. Similar virus distribution could be ob-
served in the lung, kidney, and spleen, particularly around
the marginal zone, at days 2, 4, 6, 8, and 10 (Fig 4 a, left;
only the spleen on days 2 and 4 is shown). Similar results
were obtained with 2   104 pfu infection dose. Until day 6,
there was no difference in tropism and the antigen amount
could be seen in the lung, kidney, and spleen. However, af-
ter 6 d a slight increase after infection with LCMV-WEAPL
variant compared to LMCV-WEWT could be observed (Fig.
4 a, right; only the spleen on days 4, 6, and 8 is shown).
These data were also consistent with LCMV titers in the
spleen assessed with the focus-forming assay. There, similar
virus titers between LCMV-WEWT and LCMV-WEAPL
could be detected in the spleen until day 8 after 200 pfu
(Fig. 4 b) or until day 6 after 2   104 pfu (Fig. 4 b) LCMV
infection. Thereafter, the LCMV-WEAPL virus displayed
higher titers compared to LCMV-WEWT (Fig. 4 b).
As an additional control experiment we examined if the
slower replicating LCMV-Armstrong strain (compared to
LCMV-WEWT or LCMV-Docile) could also induce pro-
tection against the WT LCMV-WE. In contrast to coin-
fection with the LCMV-WEAPL, infection with 100-fold
excess of 2   104 pfu LCMV-Armstrong did not prevent
or delay disease and death caused by infection with 200 pfu
LCMV-WEWT (Fig. 5, a and b) or by LCMV-Docile (un-
Figure 2. Delay of virus-induced immunopathology af-
ter immunization with APL peptide gp61-75R. (a, b, and
d) Smarta1 mice were infected with 20 or 200 pfu LCMV-
WEWT. 200  g gp61-75R ( , n   5 in combination with
20 pfu LCMV-WEWT and n   4 in combination with 200
pfu LCMV-WEWT) or 200  g VSV-P8 peptide ( , n   3)
were injected in IFA s.c. on days 0 and 4, respectively. The
control mice ( , n   3) were left untreated. Bodyweight
and mortality are indicated. (c and e) Activation of blood
CD4  T cells was examined by CD69 up-regulation by
FACS® analysis. (c) Statistically significant differences were
observed between the following groups (P   0,05):   ver-
sus   at days 7 and 11 and (e)   versus   at day 4.1043 Hunziker et al.
published data). In addition, protection was not observed if
LCMV-Armstrong was given 1 d before or after infection
with LCMV-WEWT or LCMV-Docile (unpublished data).
To assess the capacity of LCMV-WEAPL in its ability
to prevent immunopathology if used several days after
LCMV-WEWT infection, Smarta1 mice were infected in-
travenously with 200 pfu LCMV-WEWT on day 0 followed
by 2   104 pfu LCMV-WEAPL on days 4–7. Under these
conditions the survival kinetics (Fig. 5 c), percentage of
bodyweight reduction (unpublished data), nor the clinical
outcome (100% mortality) were influenced.
This study shows that CD4  T cell antagonism by live
LCMV-WEAPL is effective against fatal immunopathology
if an equal dose of LCMV-WEWT or a 100-fold excess
against LCMV-Docile are used. Antagonistic APLs prevent
or decrease the activation of T cells by their specific agonis-
tic peptide. How this functions in detail is not clear yet at
the molecular level (1) and was not the aim of this study.
The gp61-75R peptide has been shown to be an antagonis-
tic APL in vitro (19).
In vivo in Smarta mice, rapid and strong tg CD4  T cell
activation seems to be associated with an earlier mortal-
ity and enhanced cachexia (compare LCMV-Docile vs.
LCMV-WEWT and LCMV-Docile vs. LCMV-Armstrong)
in Smarta mice (Fig. 1), whereas delayed activation can be
protective (after a certain time point the Smarta mice are
protected from death, although similar activation levels
might be observed at a later time point). In contrast to a re-
cent study analyzing wasting disease in the absence of
CD8  T cells after intracranial LCMV infection (29), the
CD4  T cell–mediated mortality in Smarta mice was asso-
ciated with the presence of the TNFR1, which is similar to
the situation found in perforin knockout mice (28).
Several mechanisms could be responsible for the ob-
served nonlethal wasting disease after LCMV-WEAPL in-
fection and the protection from LCMV-WEWT–induced
immunopathology by the LCMV-WEAPL: (a) LCMV-
WEAPL replicates slower than LCMV-WEWT or LCMV-
Armstrong and induces a slower CD4  T cell priming that
might allow the survival of the infected Smarta mice.
However, the data presented in Fig. 4, which show a com-
parable early replication kinetic and tropism of LCMV-
WEAPL and LCMV-WEWT, argues against this. (b) LCMV-
WEAPL replicates much faster than LCMV-WEWT and
therefore most APC present the antagonistic peptide
(gp61-75R) on their MHC class II molecule. As stated
above, this is rather unlikely, because the early replication
kinetic of LCMV-WEAPL and LCMV-WEWT is compara-
ble (Fig 4; days 0–6 and day 8). However, this effect might
be responsible for the observed protection when LCMV-
WEAPL was used at a 100 times higher dose (Fig. 3, a and
b) and this dose dependence is characteristic of antagonistic
Figure 3. LCMV-APL prevents lethal immunopathol-
ogy of LCMV-WEWT and LCMV-Docile. (c) Smarta1
mice were infected with 200 pfu LCMV-WEWT (  ),
LCMV-Docile ( ), LCMV-Docile plus 200 pfu LCMV-
WEAPL ( ), LCMV-WEWT plus 200 pfu LCMV-WEAPL
( ), LCMV-WEWT plus 2   104 pfu LCMV-WEAPL ( ),
or LCMV-Docile plus 2   104 LCMV-WEAPL. (a) Sur-
vival rate (n   4 per group) and (b) bodyweight reduction
are shown. (c) The activation of blood CD4  T cells was
measured by CD69 up-regulation and (d) CD62L down-
regulation. (e) Virus titers were measured in blood. (b–e)
200 pfu LCMV-Docile (n   3), LCMV-WEWT (n   3).
Coinfection of groups is n   4 per group. Statistically sig-
nificant difference between the following groups (P  
0.05): (c)   versus   at days 4 and (c and d) 7 and (d)  
versus   at day 7; (c)   versus   at days 4, (d) 7, and (c)
12 and   versus   at (c) days 4, (d) 7, and (c) 12.1044 Protection from Immunopathology by Altered Peptide Ligand Virus In Vivo
or partial agonistic APLs. (c) After the coinfection of
Smarta mice with LCMV-WEAPL and LCMV-WEWT,
both viruses are present in the lymphoid tissue at an equal
or comparable amount when using equal infection doses
and therefore the antagonistic peptide alters and delays the
CD4  T cell activation. The experiments with LCMV-
Armstrong show that a delayed CD4  T cell activation can
result in reduced and delayed immunopathology with pos-
sible reduction of mortality.
According to our results the mechanism of protection is
most likely mediated by the delayed, and in certain cases
the reduced, activation of the gp61-specific CD4  T cells
by presenting an antagonistic APL.
It is clear that these results have model characteristics for
two reasons. First, we used a CD4  TCR tg mouse largely
lacking CD8  T cells for a defined readout and second, only
combined infection but not later superinfection was effective.
Nevertheless, we can hypothesize that during infection with
Figure 4. No relevant difference in viral tropism
and early virus titers between LCMV-WEWT and
LCMV-WEAPL. (a) C57BL/6 mice were infected
with 200 (left) or 2    104 pfu (right) LCMV-
WEWT or LCMV-WEAPL. Viral distribution was
analyzed by immunohistochemistry on cryosections
using the anti-LCMV nucleoprotein-specific rat
monoclonal antibody VL-4. Section from the
spleen are shown 2 and 4 d after infection with 200
pfu and 4, 6, and 8 d after infection with 2   104
pfu. (b) Spleen titers after infection with 200 (left)
or 2   104 pfu (right) LCMV-WEWT ( , n   3) or
LCMV-WEAPL ( , n   3).
Figure 5. T cell antagonistic features are specific for
LCMV-APL. (a and b) Smarta 1 mice were infected
with 200 pfu LCMV-WEWT ( , n   3), LCMV-Arm-
strong ( , n   3), or LCMV-WEWT plus 2   104 pfu
LCMV-Armstrong ( , n   4). (a) Body weight reduc-
tion and mortality rate are shown and (b) blood CD4 
T cell activation was measured by CD69 up-regula-
tion. (c) Limited effect of APL virus at later time
points. Smarta 1 mice were infected with 200 pfu
LCMV-WEWT. At days 4, 5, 6, and 7 mice were in-
fected with 2   104 pfu LCMV-WEAPL ( , n   4).
Control animals ( , n   3) received PBS. Survival rate
is shown.1045 Hunziker et al.
high viral loads of HIV or during chronic hepatitis B or C
such a fine-tuned mechanism may tip the virus-host-virus
balances favorably away from immunopathology. During
these infections, quasispecies with theoretical APL capacities
have been shown to arise (14, 16) and therefore APL-express-
ing mutants may influence the overall balance between lethal
immunopathology and host survival in these persistent viral
infections in humans. Although an APL strategy may offer
only limited protection against already well-activated CD4  T
cells, it may operate in chronic, persistent immunopathologi-
cal viral infections where new T cells are activated cyclically.
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